Developer docs
API playgroundTry for free, no card

Search company profiles

Laxai Pharma

Full company profile

uuid0037d7f

Namestring
Laxai Pharma
Websiteurl
laxai.com
Company typeenum
Private
Founded yearint
2004
Descriptiontext

Laxai Pharma (LAXAI) is a contract research organization (CRO) providing integrated services across the drug discovery and development spectrum. The firm was founded in 2004, is headquartered in Tampa, Florida, and reports a headcount in the 51–100 range, consistent with a mid-sized CRO operating across medicinal chemistry, biology, and development services rather than a large-scale CDMO or Big-Pharma services franchise. Its website is www.laxai.com, and its equity trades on the OTC Pink market under symbol LAXAF, with a delisted status that suggests the company is no longer actively listed on a recognized exchange. The company's co-founder and director, Vamsi Maddipatla, remains in a leadership role, providing continuity from founding.

Business-model and customer detail in the source material is sparse: no customer logos, segment mix, pricing schedule, or revenue figure is disclosed. The available commercial signal is a Q1 2026 SOCMA membership, indicating the firm remains engaged with the U.S. specialty and contract chemicals trade association and is operationally active. The only documented inorganic move is the 2010-03-11 acquisition of OSR Solutions, for an undisclosed consideration, which broadened LAXAI's service portfolio early in its operating history. No subsequent M&A, fundraising, product launch, partnership, or geographic expansion is recorded in the input data, leaving the present commercial footprint — clients served, therapeutic areas covered, geographic reach, and revenue scale — substantially undocumented for analytical purposes.

Short descriptiontext

Laxai Pharma is a Tampa-based, mid-sized contract research organization (CRO) founded in 2004 that provides integrated drug discovery and development services to pharmaceutical sponsors, operating with 51–100 employees under co-founder Vamsi Maddipatla.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersTampa, United States
HQ citystring
Tampa
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
contract research services, drug discovery development, pharmaceutical research, preclinical research services, clinical development support
Industry2 codes
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Contract Research Organization (CRO) Services
Social media profiles1 record
Cost components3 values
Personnel, Operations, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Laxai Pharma is a Contract Research Organization (CRO) that provides integrated research services across the drug discovery and development spectrum. Its service portfolio spans medicinal chemistry, biology, DMPK, and clinical development, serving pharmaceutical and biotech sponsors that need external scientific capacity to advance therapeutic programs.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Integrated Drug Discovery and Development Services
CategoryContract Research Organization (CRO) Services
Description

Integrated Contract Research Organization services spanning medicinal chemistry, biology, DMPK, and clinical development, delivered to pharmaceutical and biotech sponsors that need end-to-end research support across the drug discovery and development spectrum.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
1Jubilant Biosys
TypeDirect peer
Description

India-based integrated discovery CRO offering medicinal chemistry, in vitro/in vivo biology, and DMPK. Closely matches Laxai's discovery CRO positioning and competes for the same US/EU sponsor outsourcing programs.

TypeBroad incumbent
Description

World's largest CRO with full clinical and laboratory services across the development spectrum. Overlaps with Laxai at the broader CRO-services level and is the dominant preferred-vendor competitor for sponsor R&D budgets.

TypeDirect peer
Description

Mid-sized CRO focused on full-service clinical development for small-to-mid biopharma. Comparable to Laxai in the mid-tier CRO positioning and similarly competes for outsourced pharma R&D budgets, though Medpace is clinical-stage focused.

TypeDirect peer
Description

Global CRO/CDMO with a major drug discovery and preclinical services platform. Directly competes with Laxai in medicinal chemistry, DMPK, and biology services for pharma sponsors, and is a primary benchmark for outsourced discovery pricing.

TypeDirect peer
Description

Discovery and preclinical services arm of Eurofins Scientific, offering medicinal chemistry, in vitro pharmacology, and DMPK. Directly comparable to Laxai's chemistry-led discovery service portfolio and serves similar small-to-mid biopharma clients.

TypeBroad incumbent
Description

Large global CRO with extensive discovery, preclinical, and safety assessment services. Directly comparable to Laxai's preclinical/discovery positioning but at vastly greater scale, serving the same pharma/biotech sponsor base.

7Syngene International
TypeDirect peer
Description

India-based integrated CRO/CDMO with strong discovery, medicinal chemistry, and biology capabilities. Highly comparable service model to Laxai's discovery-focused positioning, often competing for the same US/EU sponsor programs.

TypeDirect peer
Description

China/UK/US-headquartered CRO offering integrated drug discovery, DMPK, and preclinical services. Closely comparable to Laxai's integrated discovery offering, with similar service scope but significantly larger scale and global footprint.

TypeEmerging player
Description

Mid-sized CRO/CDMO offering drug discovery, DMPK, and formulation services with US-China operations. Comparable to Laxai in the integrated discovery niche, often competing on cost for small-molecule programs.

TypeBroad incumbent
Description

Major clinical and preclinical CRO spun out from Labcorp, offering discovery through Phase IV services. Comparable to Laxai as a full-spectrum development CRO but at vastly larger scale, with broader sponsor relationships.

Market position
Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Laxai Pharma

Contract Research Organization (CRO) Serviceslaxai.com

Laxai Pharma is a Tampa-based, mid-sized contract research organization (CRO) founded in 2004 that provides integrated drug discovery and development services to pharmaceutical sponsors, operating with 51–100 employees under co-founder Vamsi Maddipatla.

What Laxai Pharma does

Laxai Pharma (LAXAI) is a contract research organization (CRO) providing integrated services across the drug discovery and development spectrum. The firm was founded in 2004, is headquartered in Tampa, Florida, and reports a headcount in the 51–100 range, consistent with a mid-sized CRO operating across medicinal chemistry, biology, and development services rather than a large-scale CDMO or Big-Pharma services franchise. Its website is www.laxai.com, and its equity trades on the OTC Pink market under symbol LAXAF, with a delisted status that suggests the company is no longer actively listed on a recognized exchange. The company's co-founder and director, Vamsi Maddipatla, remains in a leadership role, providing continuity from founding.

Business-model and customer detail in the source material is sparse: no customer logos, segment mix, pricing schedule, or revenue figure is disclosed. The available commercial signal is a Q1 2026 SOCMA membership, indicating the firm remains engaged with the U.S. specialty and contract chemicals trade association and is operationally active. The only documented inorganic move is the 2010-03-11 acquisition of OSR Solutions, for an undisclosed consideration, which broadened LAXAI's service portfolio early in its operating history. No subsequent M&A, fundraising, product launch, partnership, or geographic expansion is recorded in the input data, leaving the present commercial footprint — clients served, therapeutic areas covered, geographic reach, and revenue scale — substantially undocumented for analytical purposes.

Laxai Pharma firmographics

Firmographics
Name
Laxai Pharma
Website
https://laxai.com
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
251–500 employees
Short description
Laxai Pharma is a Tampa-based, mid-sized contract research organization (CRO) founded in 2004 that provides integrated drug discovery and development services to pharmaceutical sponsors, operating with 51–100 employees under co-founder Vamsi Maddipatla.
Ownership category
akta.pro rank

Laxai Pharma industry classification

Industry
Product category
Contract Research Organization (CRO) Services
NAICS
Scientific Research and Development Services (5417)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)

Keywords

  • Contract research services
  • Drug discovery development
  • Pharmaceutical research
  • Preclinical research services
  • Clinical development support

Where Laxai Pharma is headquartered

Location

Headquarters

HQ city
Tampa
HQ country
United States
HQ region
North America

Markets served

Laxai Pharma business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D

Laxai Pharma product offering

Product offering

Core offering

Laxai Pharma is a Contract Research Organization (CRO) that provides integrated research services across the drug discovery and development spectrum. Its service portfolio spans medicinal chemistry, biology, DMPK, and clinical development, serving pharmaceutical and biotech sponsors that need external scientific capacity to advance therapeutic programs.

Differentiator

Problem solved

Functional benefit

Products and services

  • Integrated Drug Discovery and Development Services Integrated Contract Research Organization services spanning medicinal chemistry, biology, DMPK, and clinical development, delivered to pharmaceutical and biotech sponsors that need end-to-end research support across the drug discovery and development spectrum.

Companies that use Laxai Pharma

Customer profile

Ideal customer profiles1 record

Laxai Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Laxai Pharma partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights2 records

Laxai Pharma competitors and assessment

Company assessment

Direct peers

  • Jubilant Biosys: India-based integrated discovery CRO offering medicinal chemistry, in vitro/in vivo biology, and DMPK. Closely matches Laxai's discovery CRO positioning and competes for the same US/EU sponsor outsourcing programs.
  • Medpace: Mid-sized CRO focused on full-service clinical development for small-to-mid biopharma. Comparable to Laxai in the mid-tier CRO positioning and similarly competes for outsourced pharma R&D budgets, though Medpace is clinical-stage focused.
  • WuXi AppTec: Global CRO/CDMO with a major drug discovery and preclinical services platform. Directly competes with Laxai in medicinal chemistry, DMPK, and biology services for pharma sponsors, and is a primary benchmark for outsourced discovery pricing.
  • Eurofins Discovery: Discovery and preclinical services arm of Eurofins Scientific, offering medicinal chemistry, in vitro pharmacology, and DMPK. Directly comparable to Laxai's chemistry-led discovery service portfolio and serves similar small-to-mid biopharma clients.
  • Syngene International: India-based integrated CRO/CDMO with strong discovery, medicinal chemistry, and biology capabilities. Highly comparable service model to Laxai's discovery-focused positioning, often competing for the same US/EU sponsor programs.
  • Pharmaron: China/UK/US-headquartered CRO offering integrated drug discovery, DMPK, and preclinical services. Closely comparable to Laxai's integrated discovery offering, with similar service scope but significantly larger scale and global footprint.

Broad incumbents

  • IQVIA: World's largest CRO with full clinical and laboratory services across the development spectrum. Overlaps with Laxai at the broader CRO-services level and is the dominant preferred-vendor competitor for sponsor R&D budgets.
  • Charles River Laboratories: Large global CRO with extensive discovery, preclinical, and safety assessment services. Directly comparable to Laxai's preclinical/discovery positioning but at vastly greater scale, serving the same pharma/biotech sponsor base.
  • Labcorp Drug Development (Fortrea): Major clinical and preclinical CRO spun out from Labcorp, offering discovery through Phase IV services. Comparable to Laxai as a full-spectrum development CRO but at vastly larger scale, with broader sponsor relationships.

Emerging players

  • BioDuro: Mid-sized CRO/CDMO offering drug discovery, DMPK, and formulation services with US-China operations. Comparable to Laxai in the integrated discovery niche, often competing on cost for small-molecule programs.

Market position

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Laxai Pharma social profiles

Digital presence

Laxai Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Laxai Pharma leadership team

Management profile

Number of profiles

Profiles1 record

Laxai Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Laxai Pharma M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Laxai Pharma

What does Laxai Pharma do?

Laxai Pharma is a Contract Research Organization (CRO) that provides integrated research services across the drug discovery and development spectrum. Its service portfolio spans medicinal chemistry, biology, DMPK, and clinical development, serving pharmaceutical and biotech sponsors that need external scientific capacity to advance therapeutic programs.

Is Laxai Pharma a public or private company?

Laxai Pharma is a private company. It is classified as unknown and is currently operating.

When was Laxai Pharma founded?

Laxai Pharma was founded in 2004. It employs 251 to 500 people.

Where is Laxai Pharma based?

Laxai Pharma is headquartered in Tampa, United States, in the North America region.

Who are Laxai Pharma's main competitors?

Direct peers on record are Jubilant Biosys, Medpace, WuXi AppTec, Eurofins Discovery, Syngene International and Pharmaron. Broad incumbents are IQVIA, Charles River Laboratories and Labcorp Drug Development (Fortrea). BioDuro is listed as an emerging player.

Does Laxai Pharma have an API?

No public API is recorded for Laxai Pharma.

What industry is Laxai Pharma in?

Laxai Pharma's product category is Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAAAA, Clinical CROs (Phase I–IV). Its NAICS code is 5417 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireA2A Pharmaceuticals Collaborates With LAXAI Life Sciences to Co-develop SARS-CoV-2 Main Proteases Inhibitors for the Treatment of COVID-19A2A Pharmaceuticals announced a collaboration with Laxai Life Sciences to co-develop SARS-CoV-2 Main Proteases (MPro) inhibitors for COVID-19 treatment. Under the agreement, A2A will design molecules using its AI-enabled computational platform SCULPT™, which Laxai will synthesize and evaluate, with both parties jointly conducting preclinical optimization and lead candidate selection. The companies aim to develop more selective targeted inhibitors rather than repurposing existing drugs or using virtual screening approaches, with potential for broad-spectrum antiviral activity against multiple viruses.GlobeNewswireLaxai Pharma, Ltd. Publishes Second Quarter Results and Adds New Business With Laxai Life Sciences, Inc.Laxai Pharma published its second quarter results for the period ended June 30, 2010, reporting $1,212,000 in revenue for the quarter and a net operating loss of $823,000. The company also received its first purchase order for chemistry-related services from its new subsidiary, Laxai Life Sciences.GlobeNewswireLaxai Pharma, Ltd. Engages Veteran Biosciences Executive to Serve as Permanent Chief Executive OfficerLaxai Pharma appointed Naren Mallakunta as permanent CEO, replacing his interim role. He brings over 23 years of management experience, including as Global Head of Business Development at GVK Biosciences. The company expects to accelerate growth through organic expansion and acquisitions.GlobeNewswireLaxai Pharma Ltd. and UTA Capital LLC Agree to Extend Term of $1.44 Million Term Loan and Reduce Its Interest RateLaxai Pharma Ltd. and UTA Capital LLC agreed to extend a $1.44 million term loan through December 15, 2010 and reduce its interest rate to 15% per annum. In exchange, Laxai granted UTA warrants to purchase up to 400,000 shares at $0.05 each, plus additional shares pro-rated on the average principal balance.GlobeNewswireLaxai Pharma Ltd. Completes Asset Purchase of a Clinical Research Services Company and Files Its Annual Report for 2009Laxai Pharma completed an asset purchase of OSR Solutions, a clinical research organization, to enter the CRO industry and cease its biofuel operations. The company invested $3.6 million, financed through debt and equity, and reported financial results for the fourth quarter and year ended December 31, 2009.GlobeNewswireLaxai Pharma, Ltd. (f/k/a NexGen Biofuels, Ltd.) Completes Asset Purchase of OSR Solutions, Inc. as Platform Acquisition for Clinical Research ServicesLaxai Pharma completed its first clinical research services acquisition by purchasing OSR Solutions for $3.6 million, including $1.5 million cash, $0.75 million notes, $0.6 million liabilities, and 5.6 million shares. The deal was financed by debt and equity, and Laxai expects OSR to be the first of several planned acquisitions.